本帖最后由 老马 于 2013-3-13 13:43 编辑 " c* w# N/ k" Z5 D2 A, N
/ r8 _: i0 U4 G X" u. e
健择（吉西他滨）+顺铂+阿瓦斯汀; t; \ [ J8 M C
Gemzar +Cisplatin + Avastin/ d9 A% M. W9 Y. p4 f. A; h
http://annonc.oxfordjournals.org/content/21/9/1804.full
) [/ U: A* T* w- \9 k- h' \* z' ^Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 5 w$ z8 F0 W7 f9 d4 S& j& c0 |
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
+ c5 ^7 G2 R: _/ tResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 7 R8 o2 U! X+ W. n$ \$ B% { g1 V
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 246)
: v$ ]' m. G+ O$ D4 ?" ]( o华为网盘附件：
) v I5 }% m8 i R( d$ s5 d s: f- ?【华为网盘】ava.JPG& v, y0 n' i4 L* X! @. _
|
显身卡
